Abstract:This review explores the evolving landscape of psoriasis treatment with a focus on the transformative impact of biologic drugs. Psoriasis, a prevalent and persistent skin condition characterized by red and scaly patches, historically relied on topical, phototherapeutic, and systemic treatments, each with limitations. The advent of biologics represents a significant advancement, offering targeted interventions by addressing specific immunologic mechanisms underlying the disease. Biologics are now considered the preferred systemic therapy for chronic moderate-to-severe plaque psoriasis, particularly when conventional treatments prove ineffective or present disadvantages. The review delineates the mechanisms of action for biologics targeting tumour necrosis factor-alpha (TNF-α), interleukin-17 (IL-17) and interleukin-23 (IL-23). Specific drugs under each category, including etanercept, infliximab, adalimumab, secukinumab, ustekinumab, and others, are detailed with recommended dosages. Biologics have demonstrated substantial effectiveness, with clinical trials and real-world studies showcasing significant improvements in disease severity and patient’s quality of life. Notably, these drugs exhibit rapid action, often yielding noticeable changes within weeks. While biologics have revolutionized psoriasis treatment, the review emphasizes the importance of judicious use due to potential side effects such as injection-site reactions and respiratory infections. Serious adverse events, including infections and autoimmune reactions, necessitate careful patient selection and monitoring for safety. In conclusion, biologics offer a precise and effective approach to psoriasis treatment, promising marked symptom improvement and enhanced quality of life. The review underscores the need for responsible utilization, considering patient-specific factors, and anticipates ongoing advancements in biologics for improved control over this chronic dermatitis.

Off-Label uses of Biologic Agents Approved for Psoriasis and Psoriatic Arthritis for Dermatological Conditions: Part I

Off-Label uses of Biologic Agents Approved for Psoriasis and Psoriatic Arthritis for Dermatological Conditions: Part II

Biologic Medications for the Treatment of Psoriasis - Main Groups and Dosing System

Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents

Emerging Treatment Regimens in Psoriasis: Are There Advantages Over Current Biologic Therapies?

Prescribing Pattern and Safety Profile of Biological Agents for Psoriasis in Real-World Practice: A Four-Year Calabrian Pharmacovigilance Analysis

Therapeutic Advances in Psoriasis: From Biologics to Emerging Oral Small Molecules

Chinese Experts Consensus on Biologic Therapy for Psoriasis #

New and emerging oral therapies for psoriasis

Newly discovered biologic agent used for psoriasis treatment

Biologics for Psoriasis

Biological Agents in Pediatric Dermatology

A Review of the Clinical Trial Landscape in Psoriasis: An Update for Clinicians

TNF-Alpha Inhibitors and Ustekinumab for the Treatment of Psoriasis: Therapeutic Utility in the Era of IL-17 and IL-23 Inhibitors

Short term efficacy of biological treatment for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis

Emerging Oral Therapies for the Treatment of Psoriasis: A Review of Pipeline Agents

Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis

Safety and Efficacy of Combining Biologic with Nonbiologic Therapies for Moderate to Severe Psoriasis: A Review

Biologics Used for Psoriasis: A Drug Utilization Study Based on Two Nationwide Danish Data Sources

Comparation of time-course, dose-effect, influencing factors and adverse events of biologics in the treatment of adults with moderate to severe plaque psoriasis

Latest Combination Therapies in Psoriasis: Narrative Review of The Literature